Therapeutic area
  • Animal health

What the technology does

The Entry-component Replication-Abortive (ECRA) vaccine strain of the African Horse Sickness Virus (AHSV) is genetically engineered to stimulate an immune response in the host animal, but not replicate and cause infection.

Advantage

ECRA AHSV vaccination with multiple serotypes is possible, giving a clear advance over existing vaccines. It does not need inactivating or cold storage for administration in the field. ECRA ECRA AHSV enters the cell normally (without the use of an adjuvant), but cannot complete a full replication cycle. The vaccine causes production of sufficient protein to elicit an immune response. ECRA AHSV can be produced at biosafety level 2, lowering production costs, and the viral titre is maintained following
dessication, enabling delivery / administration in the field in the absence of refrigeration. Horse trials using ECRA AHSV cocktails against multiple serotypes have been successfully conducted.

Main application field

Therapeutic

Status

This opportunity is available for licencing and co-development.

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities